Phase 1 Study of ALZT-OP1 Combination Therapy in Normal Healthy Volunteers

NCT ID: NCT02482324

Last Updated: 2015-07-21

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 26 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-06-30
• Study Completion Date: 2015-07-31

Brief Summary

This is an open-labeled, cross-over design, pharmacokinetic study, to determine the pharmacokinetics of ALZT-OP1 (a combination drug therapy) designated as ALZT-OP1a and ALZT-OP1b, in both plasma and CSF, following co-administration of the active compounds, in healthy volunteers, aged 55-75, and in good general health.

Detailed Description

This is an open-labeled, cross-over design, pharmacokinetic study, where 24 subjects will be randomly assigned to receive treatment regimen A-B or B-A on two consecutive days of dosing.

Two dosing groups are planned for the study :

• Group 1 (n=12)
• Group 2 (n=12)

Each group will be admitted to the Phase I Unit the evening before dosing and will initiate dosing the next morning for 2-days of consecutive treatment (A-B, or B-A). Both groups will undergo identical study related procedures, except those subjects that consent to CSF collection on Day 1 of dosing.

Dose regimen A consists of a single inhaled oral dose of ALZT-OP1a via dry powder inhaler + a single oral tablet dose of ALZT-OP1b.

Dose regimen B consists of two oral inhaled doses of ALZT-OP1a, not more than 2 minutes apart, via dry powder inhaler + two oral tablet doses of ALZT-OP1b.

Plasma Collection, All Subjects (n=24) 1 mL blood samples will be collected at T: 0, 5, 10, 15, 30, 1 hr, 2 hr, 4 hr, and 6 hours, following ALZT-OP1 administration (Days 1 and 2).

CSF Collection, Sub-group (n=12) A sub-group of 12 subjects will be consented for CSF collection.

1 mL of CSF will be collected at T: 0, 5 min, 30 min, 2 hr, and 4 hours, following ALZT-OP1 administration (Day 1 only).

Conditions

Healthy Volunteers

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Blinding Strategy: NONE

Study Groups

Treatment A-B

12 subjects will receive a single oral inhaled dose of ALZT-OP1a, via dry powder inhaler, and a single oral tablet dose of ALZT-OP1b on Day 1, and two doses of ALZT-OP1a and ALZT-OP1b on Day 2, within two minutes of each other. All subjects will have plasma collected for PK analysis and 6 of 12 consented subjects from this group will provide CSF samples for analysis. CSF collected on Day 1 only.

Group Type: OTHER

ALZT-OP1a

Intervention Type: DRUG

Mast cell stabilizer

ALZT-OP1b

Intervention Type: DRUG

anti-inflammatory

Dry Powder Inhaler

Intervention Type: DEVICE

The inhaler will be used to deliver ALZT-OP1a via oral inhalation for both days on study.

Treatment B-A

12 subjects will receive two oral inhaled doses of ALZT-OP1a, via dry powder inhaler, and two oral tablet doses of ALZT-OPb, within two minutes of each other, on Day 1, and single doses of ALZT-OP1a and ALZT-OP1b on Day 2. All subjects will have plasma collected for PK analysis and 6 of 12 consented subjects from this group will provide CSF samples for analysis. CSF collected on Day 1 only.

Group Type: OTHER

ALZT-OP1a

Intervention Type: DRUG

Mast cell stabilizer

ALZT-OP1b

Intervention Type: DRUG

anti-inflammatory

Dry Powder Inhaler

Intervention Type: DEVICE

The inhaler will be used to deliver ALZT-OP1a via oral inhalation for both days on study.

Interventions

ALZT-OP1a

Mast cell stabilizer

Intervention Type: DRUG

ALZT-OP1b

anti-inflammatory

Intervention Type: DRUG

Dry Powder Inhaler

The inhaler will be used to deliver ALZT-OP1a via oral inhalation for both days on study.

Intervention Type: DEVICE

Other Intervention Names

Cromolyn, Intal; ibuprofen

Eligibility Criteria

Inclusion Criteria

• Provide a signed written informed consent;
• Age 55-75 inclusive;
• ECG within normal limits;
• Body mass index (BMI) ≥ 18 kg/m2 and ≤ 30 kg/m2;
• Negative urine drug screen for selected drugs of abuse at screening;
• Negative for hepatitis and HIV at screening;
• Good general health, as determined by medical history, physical examination, and clinical laboratory testing;
• Willingness to stay in the unit overnight for the duration of the study;
• Consent for CSF collection (for those in CSF group).

Exclusion Criteria

• Current smokers, or ex-smokers with a remote history (> 100 pack/year);
• Clinically significant medical conditions;
• History of ECG abnormalities;
• Symptomatic viral infection, or suspicion thereof (including rhinitis) in the last 14 days prior to dosing;
• Signs of active pulmonary infection or other pulmonary inflammatory conditions, even in absence of febrile episodes, in the last 14 days;
• History or presence of disease in the kidneys and/or heart, lungs, liver, gastrointestinal tract, endocrine organs or other conditions such as metabolic disease known to interfere with the absorption, distribution, metabolism, and excretion of drugs;
• Malignancy, regardless of location;
• Autoimmune disorders such as (but not limited to) lupus erythematosus, multiple sclerosis, rheumatoid arthritis, or sarcoidosis;
• Investigational agents are prohibited one month prior to entry and for the duration of the trial;
• Currently taking medications known to be CYP2C9 inducers (i.e. carbamazepine and rifampicin);
• Currently taking cromolyn, or have taken cromolyn, within the past 30 days;
• NSAID use (products containing ibuprofen while on study);
• Aspirin, or products containing aspirin, while on study;
• Allergy or hypersensitivity to cromolyn (also known as Intal®, Nasalcrom®, etc.);
• Allergy or hypersensitivity to ibuprofen (Advil®, Motrin®, Nuprin®, etc.) or aspirin, including Stevens-Johnson syndrome;
• History of hypersensitivity or allergies to any of the drug compound under investigation (cromolyn, ibuprofen, lactose, or magnesium stearate);
• History of clinically significant respiratory disorders and chronic respiratory disease with impaired respiratory effort or difficulty taking inhaled drugs (examples: COPD, emphysema);
• Abnormal pulmonary function test, defined for this protocol as: FEV1/FVC < 70% of the predicted value for the subject, when compared to reference values; AND FEV1 and FVC < 70% of predicted value when compared to reference values, indicating moderate to severe respiratory obstruction;
• Any other disease or condition, which, in the opinion of the investigator, would make the subject unsuitable for this study;
• Female subjects of reproductive potential with a positive pregnancy test (urine or serum) or who are pregnant or lactating.

• Minimum Eligible Age: 55 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Panax Clinical Research

OTHER

Sponsor Role: collaborator

Pharma Consulting Group AB

INDUSTRY

Sponsor Role: collaborator

KCAS

UNKNOWN

Sponsor Role: collaborator

AZTherapies, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

David Elmaleh, PhD

Role: STUDY_CHAIR

Study Sponsor

David Brazier, BS

Role: STUDY_DIRECTOR

Study Sponsor

Locations

Panax Clinical Research

Miami Lakes, Florida, United States

Countries

United States

Other Identifiers

AZT-002

Identifier Type: -

Identifier Source: org_study_id